Table 3 Adverse events in the guselkumab group and adalimumab group
Case no. | Group | Adverse events | CTCAE grade |
|---|---|---|---|
1 | Guselkumab | None | |
2 | Guselkumab | 3M: hepatic disfunction | 1 |
3 | Guselkumab | None | |
4 | Guselkumab | None | |
5 | Guselkumab | None | |
6 | Guselkumab | None | |
7 | Guselkumab | None | |
8 | Guselkumab | None | |
9 | Guselkumab | None | |
10 | Guselkumab | 2M: conjunctival injection (discontinuation of guselkumab) | 1 |
11 | Guselkumab | None | |
12 | Guselkumab | None | |
13 | Adalimumab | 2M: psoriasis-like rash (discontinuation of adalimumab) | 1 |
14 | Adalimumab | None | |
15 | Adalimumab | None | |
16 | Adalimumab | None | |
17 | Adalimumab | 5M: psoriasis-like rash (discontinuation of adalimumab) | 1 |
18 | Adalimumab | None | |
19 | Adalimumab | None | |
20 | Adalimumab | None | |
21 | Adalimumab | None | |
22 | Adalimumab | 1M: gastroenteritis | 1 |
23 | Adalimumab | None | |
24 | Adalimumab | 4M: inadequate response (discontinuation of adalimumab) | 1 |
25 | Adalimumab | 1M: psoriasis-like rash (discontinuation of adalimumab) | 2 |